Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Shock

Shock

59

Pipeline Programs↗

97

Active Trials↗

35

Companies Involved↗

Shock is a moderately active landscape with 59 programs across 35 companies. 13 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

73/100

Mech. Concentration

15/100

Completion Rate

80/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical41

Caspofungin

Fresenius Kabi Taiwan Ltd.

Fluid Resuscitation

University of Zurich

Medtronic IN.PACT (DCB)

Shockwave Medical, Inc.

Daptomycin

Baxter Healthcare Corporation

Doripenem

Shionogi

Phase 11

Packed Red Blood Cells

NYU Langone Health

Phase 24

Nangibotide

Inotrem

Methylprednisone

Astellas

Sevoflurane

AbbVie

ARTICE

Artcline GmbH

Phase 313

Hydrocortisone Sodium Succinate

National Cancer Institute (NCI)

Centhaquine

Pharmazz, Inc.

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Methylene Blue

Provepharm SAS

Landiolol

Aultman Health Foundation

Approved

No programs

Analysis

Modality Breakdown

96%

Small molecule

53 of 55 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 55 classified programs, each share of the total. Modality classified for 100% of 59 pipeline programs.

Analysis

Trial Status

387

clinical trials

Completed172 · 44%

Unknown status75 · 19%

Recruiting54 · 14%

Not yet recruiting36 · 9%

Terminated27 · 7%

Withdrawn14 · 4%

Other9 · 2%

Clinical Trials

Trial Activity

387 trials

Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients

Recruiting·—·Preclinical·NCT06140147·1,850 enrolled

A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock

Recruiting·PPharmazz, Inc.·Approved·NCT05956418·400 enrolled

Prevalence of the Aortic to Radial Pressure Gradient in States of Shock

Recruiting·HHospices Civils de Lyon·N/A·NCT06460519·180 enrolled

Clinical Evaluation of Using NIRSense Sensor Patch to Measure Microvascular Perfusion Responses and Predict Decompensation in Cardiogenic Shock Patients

Recruiting·NNIRSense Inc.·N/A·NCT07825363·20 enrolled

Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding

Recruiting·—·Phase 3·NCT06070350·1,000 enrolled

Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE

Recruiting·UUniversity Hospital, Lille·Phase 1·NCT05699005·236 enrolled

Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.

Recruiting·UUniversity Medical Centre Maribor·N/A·NCT06539234·121 enrolled

Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Invobenitug Also Known as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations.

Recruiting·44TEEN4 Pharmaceuticals GmbH·Preclinical·NCT06832722·90 enrolled

Effect of the oXiris Hemofilter on Early Endotoxin Burden in Patients With Septic Shock Requiring Continuous Renal Replacement Therapy: A Single-Center, Prospective, Single-Arm Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Preclinical·NCT07807410·13 enrolled

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

Recruiting·—·Approved·NCT06693726·20 enrolled

Efficacy and Safety of SynFlow Duro System in the Treatment of Post Cardiotomy Cardiogenic Shock: a Prospective, Multicenter, Single-arm Clinical Trial

Recruiting·FForQaly Medical (Shanghai) Co., Ltd·Preclinical·NCT07560085·60 enrolled

A framEwork for aN InteGrated assessMent of cArdiac Rehabilitation Programs in Patients Acutely Managed for Cardiogenic Shock - ENIGMA-shock

Recruiting·FFondazione Don Carlo Gnocchi ETS·N/A·NCT06572826·2,000 enrolled

Rapid Impella Support and Escalation Trial

Recruiting·UUniversity Hospital of Cologne·N/A·NCT07655479·115 enrolled

Microcirculatory Effects of Empagliflozin in Patients With Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

Recruiting·UUniversity Hospital, Strasbourg, France·Preclinical·NCT07141355·24 enrolled

Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial

Recruiting·UUniversity Hospital, Strasbourg, France·Approved·NCT06881927·212 enrolled

Page 1 of 26

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)